Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AYTU
stocks logo

AYTU

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q3
FY2026Q4
12.51M
-22.89%
-0.600
-561.54%
13.39M
-27.46%
-0.465
-321.43%
15.92M
+5.16%
-0.275
-90.58%
Estimates Revision
The market is revising Downward the revenue expectations for Aytu BioPharma, Inc. (AYTU) for FY2026, with the revenue forecasts being adjusted by -8.94% over the past three months. During the same period, the stock price has changed by -0.44%.
Revenue Estimates for FY2026
Revise Downward
down Image
-8.94%
In Past 3 Month
EPS Estimates for FY2026
Revise Downward
down Image
-30.06%
In Past 3 Month
Stock Price
Go Down
down Image
-0.44%
In Past 3 Month
Wall Street analysts forecast AYTU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AYTU is 9.17 USD with a low forecast of 7.00 USD and a high forecast of 12.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast AYTU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AYTU is 9.17 USD with a low forecast of 7.00 USD and a high forecast of 12.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.240
sliders
Low
7.00
Averages
9.17
High
12.50
Current: 2.240
sliders
Low
7.00
Averages
9.17
High
12.50
Maxim
Buy
maintain
$9 -> $7
2025-09-25
Reason
Maxim
Price Target
$9 -> $7
2025-09-25
maintain
Buy
Reason
Maxim lowered the firm's price target on Aytu BioPharma to $7 from $9 and keeps a Buy rating on the shares. The firm cites the company's Q4 and adjusted EBITDA miss, and while the quarter was the 9th straight quarter of positive adjusted EBITDA, its base business - ADHD+pediatrics - has effectively peaked, the analyst tells investors in a research note. Maxim adds however that in June, Aytu announced it signed an exclusive commercialization agreement with Fabre-Kramer Pharmaceuticals to commercialize EXXUA, and the firm believes that EXXUA is a transformational asset that can accelerate growth beyond the current ADHD franchise.
Maxim
Buy
downgrade
$9 -> $7
2025-09-24
Reason
Maxim
Price Target
$9 -> $7
2025-09-24
downgrade
Buy
Reason
Maxim lowered the firm's price target on Aytu BioPharma to $7 from $9 and keeps a Buy rating on the shares.
Lake Street
Buy
initiated
$8
2025-07-01
Reason
Lake Street
Price Target
$8
2025-07-01
initiated
Buy
Reason
Lake Street initiated coverage of Aytu BioPharma with a Buy rating and $8 price target. The firm beleives new entrants can make a dent in the crowded antidepressant market, particularly those that have some level of differentiation, the analyst tells investors in a research note. The firm's research indicates strong interest in Aytu's EXXUA as an alternative for patients with major depressive disorder, and says the launch will materially alter Aytu's financial profile, powering revenues to record levels already in FY27. Lake Street adds that substantial upside remains as generic overhang is resolved "one way or the other" and the EXXUA launch performance ramps at or above expectations.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Aytu Biopharma Inc (AYTU.O) is -2.42, compared to its 5-year average forward P/E of -1.90. For a more detailed relative valuation and DCF analysis to assess Aytu Biopharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.90
Current PE
-2.42
Overvalued PE
4.39
Undervalued PE
-8.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.46
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
8.44
Undervalued EV/EBITDA
-11.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.41
Current PS
0.00
Overvalued PS
0.89
Undervalued PS
-0.07
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 541.02% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 541.02% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

AYTU News & Events

Events Timeline

(ET)
2025-10-28
09:17:14
Aytu BioPharma reveals extension of patent duration for EXXUA
select
2025-06-30 (ET)
2025-06-30
05:19:35
Aytu BioPharma initiated with a Buy at Ascendiant
select
2025-06-25 (ET)
2025-06-25
08:27:07
Aytu BioPharma appoints Gerwin Westfield as SVP, scientific affairs
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-19NASDAQ.COM
Nutex Health Rises 21% in After-Hours Trading Following Revenue Increase; Biotech Competitors Also See Gains on Tuesday

  • Nutex Health's Performance: Nutex Health Inc. saw a significant after-hours surge of 20.97% to $120.00 following a quarterly report that revealed a net loss of $17.7 million but a remarkable 220.7% increase in revenue year-over-year to $244.0 million.

  • Bullfrog AI Holdings Update: Bullfrog AI Holdings, Inc. gained 5.87% to $0.9798 in after-hours trading, likely due to investor positioning ahead of its upcoming technical presentation at the AI Drug Discovery & Development Summit 2025.

  • Clearside Biomedical's Recovery: Clearside Biomedical, Inc. rose 6.51% to $3.27 after reporting a narrower net loss of $5.97 million, although its revenue fell sharply to $201 thousand from $1.04 million a year ago.

  • Aytu BioPharma and OKYO Pharma Developments: Aytu BioPharma, Inc. climbed 8.91% to $2.20 after reporting a first-quarter net income increase, while OKYO Pharma Limited edged up 2.44% to $2.18, preparing for a presentation on its investigational drug candidate for neuropathic corneal pain.

[object Object]
Preview
9.5
11-14Yahoo Finance
Aytu BioPharma Inc (AYTU) Q1 2026 Earnings Call Summary: Robust Performance of ADHD Portfolio

  • Financial Performance: Aytu BioPharma reported net revenue of $13.9 million for the quarter, driven by a 10% increase in their ADHD portfolio, although overall revenue decreased from the previous year due to a one-time rebate benefit.

  • Product Launch and Patent Extension: The company is on track to launch its new product, Exua, by the end of 2025, and has successfully extended the Exua method of use patent to September 2030, enhancing its market exclusivity.

  • Operational Investments: Operating expenses rose to $10.2 million as the company invested in the Exua launch, contributing to a negative adjusted EBITDA of $0.6 million for the quarter.

  • Market Strategy and Feedback: Aytu is focusing on engaging prescribers for Exua, targeting younger patients dissatisfied with current medications, and expects better coverage from payers compared to its ADHD products.

[object Object]
Preview
9.5
11-14NASDAQ.COM
Applied Therapeutics, Omeros, and Others Experience Significant Price Changes After Market Close

  • Milestone Scientific Inc. Earnings: Milestone Scientific's shares rose 36.10% after reporting a third-quarter net loss of $1.2 million, with revenue slightly down to $2.4 million due to weaker domestic dental sales but stronger international demand.

  • Applied Therapeutics Inc. Update: Applied Therapeutics saw a 14.78% increase in shares after narrowing its Q3 net loss to $19 million and announcing a meeting with the FDA to discuss the regulatory path for govorestat in Classic Galactosemia.

  • Omeros Corp. Financial Results: Omeros Corp. shares gained 20.54% following a Q3 net loss of $30.9 million, with an update on its Biologics License Application for narsoplimab and an extended FDA action date to December 2025.

  • The Oncology Institute Inc. Performance: The Oncology Institute's shares rose 19.48% after reporting a 36.7% increase in Q3 revenue to $136.6 million, while also raising its full-year revenue guidance to between $495 million and $505 million.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Aytu Biopharma Inc (AYTU) stock price today?

The current price of AYTU is 2.24 USD — it has increased 5.16 % in the last trading day.

arrow icon

What is Aytu Biopharma Inc (AYTU)'s business?

Aytu BioPharma, Inc. is a pharmaceutical company focused on advancing medicines for complex central nervous system (CNS) diseases. Its business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies and which primarily consists of two product portfolios. Its Attention Deficit Hyperactivity Disorder (ADHD) portfolio consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) , Cotempla XR-ODT, and METADATE CD, which are CNS stimulants indicated for the treatment of ADHD in patients. Its Pediatric portfolio consists of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, Poly-Vi-Flor, and Tri-Vi-Flor. EXXUA is indicated to treat depressive disorder (MDD) in adults.

arrow icon

What is the price predicton of AYTU Stock?

Wall Street analysts forecast AYTU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AYTU is 9.17 USD with a low forecast of 7.00 USD and a high forecast of 12.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Aytu Biopharma Inc (AYTU)'s revenue for the last quarter?

Aytu Biopharma Inc revenue for the last quarter amounts to 13.89M USD, decreased -16.21 % YoY.

arrow icon

What is Aytu Biopharma Inc (AYTU)'s earnings per share (EPS) for the last quarter?

Aytu Biopharma Inc. EPS for the last quarter amounts to -0.08 USD, decreased -46.67 % YoY.

arrow icon

What changes have occurred in the market's expectations for Aytu Biopharma Inc (AYTU)'s fundamentals?

The market is revising Downward the revenue expectations for Aytu BioPharma, Inc. (AYTU) for FY2026, with the revenue forecasts being adjusted by -8.94% over the past three months. During the same period, the stock price has changed by -0.44%.
arrow icon

How many employees does Aytu Biopharma Inc (AYTU). have?

Aytu Biopharma Inc (AYTU) has 82 emplpoyees as of December 05 2025.

arrow icon

What is Aytu Biopharma Inc (AYTU) market cap?

Today AYTU has the market capitalization of 22.82M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free